share_log

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

Benzinga Real-time News ·  Sep 8, 2022 18:18
  • The United States Food and Drug Administration (FDA) has approvedRevance Therapeutics' (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines (glabellar lines) in adults. Revance shares traded as high as 22.39 percent, in a range of $22.02 to $25.47 on day volume of 8.73 million shares versus three months average volume of 729.3 thousand shares, closed regular trading session at $25.30.
  • Silence Therapeutics (NASDAQ:SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera (PV). Silence Therapeutics shares traded as...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment